
Index

A

Acetylcholinesterase inhibitors, 80, 81
Actively listening, 153
Acute brain injuries, 4, 178
 See also Severe acute brain injury
Addiction, 247
Advance directives (ADs), 14
Affective behaviors, 39
Agitation, 258
Akinetic mutism, 41
ALS, *see* Amyotrophic lateral sclerosis (ALS)
Alternative bias, 179
Amantadine, 48, 65
Ambiguity aversion, 179
Amyotrophic lateral sclerosis (ALS), 187
 advance care planning and goals of care, 105
 caregiver burden, 111
 DMD, 104, 105
 education agenda, 112
 EOL care and hospice, 111, 112
 estimating prognosis, 102
 functional rating scale, 103
 hasten death, 196, 197
 hastened death, requests for, 111
 modifying therapy
 edaravone, 103
 riluzole, 103
 SMA, 104
 pain, 241
 research agenda, 112
 serious illness triggers, 111
 symptomatic management of, 106
 symptoms and management
 cognitive dysfunction, 109
 cramps, 109
 dysarthria and communication issues, 109, 110
 dysphagia, 105, 107
 insomnia, 110
 mood disorders, 108
 pain, 109
 pseudobulbar affect, 108
 sialorrhea, 110
 spasticity, 107, 108
 weakness, 108

 withdrawing and withholding life sustaining
 treatments, 110, 111

Anger, 262
Anhedonia, 189
Antibiotic therapy, 211
Anti-epileptics, 123, 232
Antipsychotics, 74, 83, 223, 233
Ask-Tell-Ask strategy, 153
Ataxia, multiple sclerosis, 94
Autonomy, 18, 62, 162, 165, 180, 190,
 214–215

B

Behavioral and psychological symptoms of dementia
 (BPSD), 76, 79
 clinical evaluation, 82
 evaluation, 81
Behavioral Pain Scale (BPS), 12
Benzodiazepines, 12, 234
Bevacizumab, 119
Biases, 179, 180
Botulinum toxin injections, 67, 110, 250
Bowel dysfunction, multiple sclerosis, 95
Brain death, 20
Brain tumors, 174, 178, 235, 241
Brief Needs Assessment Tool (BNAT), 298
Brief palliative care needs assessment tool (B-NAT), 298
Bromocriptine, 33
Burnout
 build lifelong habits and practices of, 275, 276
 building resilience, 272, 274, 275
 choice, 273
 connection, 273
 happiness, 273
 personal resources, 273
 practices, 274, 275
 definitions, 269, 270
 education and research agenda, 276
 neurology and palliative care, 270
 popular myth, de-bunking, 271
 preventing and reducing, 271, 272
 risk factors, 270, 271
 symptoms, 270

C

Cannabis, 68, 94, 245
 Carbamazepine, 245
 Cardiopulmonary resuscitation (CPR), 179
 Career dissatisfaction, 269
 Caregiver(s)
 assessing needs, 285, 287
 categories, needs and potential responses, 286
 education and research agenda, 288–289
 impact on, 282–284
 importance of, 280, 281
 malignant brain tumors, 125, 126
 needs, 284, 285
 providing support to, 287, 288
 roles, 281, 282
 timeline and nature of, 281
 triggers, 287
 Caregiver burden
 neuromuscular diseases, 111
 Parkinson disease, 68, 69
 Central pain, 240
 Chemotherapy, 118, 125
 Cheyne-Stokes breathing, 235
 Child neurology
 end of life care
 bereavement, 143
 care of the family, 142, 143
 making memories, 142
 estimating and communicating prognosis, 136
 communicating prognostic uncertainty, 137, 138
 prognostic tools, 136, 137
 prognostication, limitations of, 137
 family, supporting
 communication, 140, 141
 family needs, 142
 shared decision making, 141, 142
 palliative care consultation, 143
 pediatric neurologic disease, triggers for serious
 conversations, 140
 pharmacologic strategies, 139
 pregnancy, infancy, childhood, and adolescence,
 neurologic conditions, 136
 research agenda, 143, 144
 symptom detection and management
 non-pain physical symptoms, 138
 pain, 138
 psychological, social and spiritual distress, 139
 Clonidine, 138
 Cognitive deficits, 4
 Cognitive dysfunction, neuromuscular diseases, 109
 Cognitive impairment, 125
 Cognitive motor dissociation (CMD), 30
 Cognitive rehabilitation, 121
 Coma, 26, 27, 30, 38, 43
 Coma Recovery Scale-Revised (CRS-R), 42
 Communication, 151
 Ask-Tell-Ask strategy, 153
 child neurology, 140, 141
 discussing prognosis, Ask-Tell-Ask strategy, 157
 medical decision, 175, 176

 NURSE Mnemonic, 154
 patient's voice, questions, 158
 REMAP framework, 158
 Communication skills, 152
 Communication tasks, serious illness
 delivering serious news and emotions, 152–155
 discussing prognosis and information needs, 156
 exploring goals of care with surrogates, 157, 158
 mapping patient's values, goals of care, 157
 Compassion, 271
 Compassion Cultivation Training, 267
 Consciousness, 31, 32
 coma to vegetative state, 27, 30
 end of life care, 33, 34
 estimating prognosis, 26, 27
 persistent disorders, categories, 31
 prolonged coma, serious conversation in, 27
 symptom detection and management
 pain, 32
 PSH syndrome, 32
 unresponsiveness, 31
 vegetative vs. minimally conscious state, 30
 Constipation, 66
 Core communication skills, 151
 Corticosteroids, 249
 Cramps, neuromuscular diseases, 109
 CRASH, 27, 28
 Critical Care Pain Observation Tool (CPOT), 12
 Cultural diversity, 259
 Cultural sensitivity, 264, 265

D

Dantrolene, 32, 94
 Daytime sleepiness, 66
 De-Biasing, 179
 Decompressive hemicraniectomy (DHC), 16
 Delirium, 232, 233
 Dementia, 73, 74, 207
 Alzheimer's disease phenotype
 advanced stages, 76
 early stages, 75
 behavioral and psychological symptoms, 81–83
 capacity evaluation, 80
 caregiver support, 83–84
 education and research agenda, 84
 end-of-life care, 84
 estimating prognosis
 prognostication, 76–78
 trajectories of death, 76
 FAST, 77
 hasten death, 197, 198
 pain, 240
 PAINAD, 82
 palliative care approach, 78
 mild dementia, 78, 79
 moderate dementia, 79
 severe (advanced) dementia, 79, 80
 Parkinson disease, 65
 serious conversations, triggers for, 78

- stages, 75
 - symptom assessment and management
 - cognitive treatment, 80, 81
 - weight loss and, 81
 - types of, 74, 75
 - Dementia with Lewy bodies (DLB), 74, 83, 198
 - Depersonalization, 269
 - Depression, 95, 122
 - Detrusor-sphincter dyssynergia, 67
 - Dexmedetomidine, 32
 - Difficult emotions, 258, 260–263
 - Difficulty managing secretions, 138
 - Dimethyl fumarate, 90
 - Disability paradox, 52
 - Disorders of consciousness (DoC), 37, 38
 - ancillary tests, 43, 44
 - arousal and awareness, 39
 - assessment, confounds in, 41
 - available behaviors, repertoire of, 39
 - caregiver experience, 49, 50
 - categories, 38
 - clinical assessment, 42, 43
 - differential diagnosis, 41, 42
 - goals of care, 50–53
 - illness trajectory, 37
 - maximizing neurological status, 47–49
 - misdiagnosis, 40, 41
 - nomenclature and nosology, 38, 40
 - pain management, 44, 45
 - prognosis and outcomes, 45–47
 - research agenda, 53, 54
 - Dizziness, 95
 - Donepezil, 121
 - Do-not-resuscitate (DNR) orders, 51
 - Dopamine agonist withdrawal syndrome (DAWS), 65
 - Droxidopa, 67
 - Drug interactions, 123
 - Duchenne muscular dystrophy (DMD), 104, 105
 - Dysarthria
 - multiple sclerosis, 94
 - neuromuscular diseases, 109, 110
 - Dysautonomia, 66, 67
 - Dysphagia, 20, 105, 107, 127
 - multiple sclerosis, 94
 - neuromuscular diseases, 107
 - Parkinson disease, 67, 68
 - Dyspnea, 84, 107, 193, 233–234
- E**
- Eastern Cooperative Oncology Group (ECOG) system, 121
 - Edaravone, 103
 - Edema, 119, 124, 234
 - Edmonton Symptom Assessment System revised for Parkinson Disease (ESAS-PD), 62, 63
 - Emotions, 102, 153, 155, 158, 260, 262
 - Electroencephalogram (EEG), 136
 - Emotional exhaustion, 269
 - Emotional well-being, 182
 - Empathy, 152–155, 188, 270, 271
 - Encephalopathy, 11, 136, 249
 - End of life (EOL) care
 - child neurology
 - bereavement, 143
 - care of the family, 142, 143
 - making memories, 142
 - consciousness, 33, 34
 - dementia, 84
 - malignant brain tumors, 126, 127
 - hospice, 128
 - nutrition, 127
 - sedation and pain control, 127, 128
 - seizure management, 127
 - medical decision making without diagnostic testing, 231
 - medical symptom management, 230, 231
 - multiple sclerosis, 96
 - neuromuscular diseases, 111, 112
 - SABI, 19, 20
 - specific symptom management
 - delirium, 232, 233
 - dyspnea, 233, 234
 - myoclonus, 233
 - pain, 234
 - research and educational agenda, 236
 - seizures, 231, 232
 - signs, 234–236
 - Engagement, 270
 - Euthanasia, *see* Voluntary active euthanasia
 - Event-related potentials (ERPs), 44
 - Expanded Disability Status Scale (EDSS), 92
- F**
- Fatigue, 122, 123
 - multiple sclerosis, 94
 - Parkinson disease, 66
 - Fear, 123, 126, 188, 197, 200, 214, 262
 - Forced vital capacity (FVC), 105
 - Framing bias, 179
 - Frontotemporal dementia (FTD), 75, 109
 - Functional assessment staging (FAST), 76, 77
- G**
- GABA agonists, 48
 - Gabapentin, 124
 - Genetic testing, 136
 - Glioblastoma, 118, 188, 198, 199
 - Gliomas, 118
 - Glucocorticoid, 104, 199
 - Grief, 2, 140, 258, 261–262, 283, 284
 - Guilt, 49, 142, 262, 285
- H**
- Halifax GRACE training, 266, 275
 - Hasten death
 - application

- Hasten death (*cont.*)
 ALS, 196, 197
 dementia, 197, 198
 glioblastoma, 198, 199
 Huntington's disease, 199
 Parkinson disease, 198
 stroke, 199, 200
 ethics, 189, 190
 evaluating requests, 188, 189
 initial patient presentation, return to, 201
 life sustaining treatment, withdrawal of, 192, 193
 methods of, 191
 PAD, 194, 195
 palliative sedation, 193, 194
 VAE, 195–196
 VSED, 194
- Headache, 4, 12, 118, 125, 125, 182, 241
- Higher-order cortex–motor dissociation (HMD), 30, 31
- Hope, 6, 13, 49, 111, 120, 192, 264, 264, 293
- Hopelessness, 4, 120, 258
- Hospice, 19
 anti-epileptics, 232
 benefit, 222
 concept of, 221
 conversation triggers, 229
 eligibility guidelines, 224
 guidelines, 225
 initiating discussions, 228, 230
 international scope, 227, 228
 malignant brain tumors, 128
 neurologist, potential roles of, 227
 neurologist's role, 226, 227
 neuromuscular diseases, 111
 origins of, 221, 222
 program, 222–223
 team, 223, 224
- Huntington's disease (HD), 188, 282, 289
 hasten death, 199
 pain, 240
- Hyperbaric oxygen therapy, 121
- I**
- IMPACT, 27, 28
- Impaired consciousness, 11, 41, 42, 48
- Impaired patient capacity, 174
- Individualized quantitative behavioral assessment (IQBA), 42
- Insomnia, 62, 82, 110, 110, 124
- Intensive care unit, 15, 136, 139, 141, 206, 209, 297
- Interdisciplinary palliative team, 295, 297
- Intracerebral hemorrhage (ICH), 164
- Isolation, 258, 259
- K**
- Karnofsky Performance Score (KPS), 121
- L**
- Lacosamide, 123, 124
- Laryngectomy, 106, 110
- Left ventricular assist devices (LVADs), 192
- Leptomeningeal disease
 epidemiology, 119
 presentation and diagnosis, 119
 treatment, 119, 120
- Levodopa, withdrawal, 68
- Lewy Body Dementia, 74, 83, 198
- Lidocaine, 245, 250
- M**
- Magnetic resonance imaging (MRI), 136
- Malignant brain tumors
 caregiver, 125, 126
 education agenda, 128
 end of life care, 126, 127
 hospice, 128
 nutrition, 127
 sedation and pain control, 127, 128
 seizure management, 127
 epidemiology, 117
 Karnofsky and ECOG performance scales, 122
 metastatic disease and leptomeningeal disease
 epidemiology, 119
 presentation and diagnosis, 119
 treatment, 119, 120
 presentation and diagnosis, 118
 prognosis for, 120
 performance scores, 121
 presenting prognosis, 120, 121
 research agenda, 128
 serious conversation triggers, 121
 symptom assessment and management
 appearance, 125
 appetite and weight, 125
 cognitive issues, 121
 edema and steroid use, 124
 existential suffering, 123
 fatigue, 122, 123
 headache, 125
 loss of independence, 125
 mood changes, 122
 seizures, 123, 124
 weakness, 124
 treatment, 118
- Meaninglessness, 258, 259
- Mechanical ventilation, 193
- Medical decision
 capacity, assessing, 175
 challenges, 181
 decision aids, 181
 diagnosis, 172
 capacity, 174
 communication, 175, 176
 medical problem, 172
 patient understanding, 172
 values and preferences, 172–174
 objective, 182
 option assessment
 assessing benefits and risks, 176, 177
 biases, 179, 180
 default options/smart defaults, 179

- diagnostic uncertainty, 178
 - prognostic uncertainty, 178
 - therapeutic uncertainty, 178
 - time limited trials, 178
 - uncertainty, 178
- patient value, assigning, 177, 181
- shared decision making, 180, 181
- Medicare, 60, 74, 77, 111, 222, 224
- Metastatic disease
 - epidemiology, 119
 - presentation and diagnosis, 119
 - treatment, 119, 120
- Methylphenidate, 19, 31, 94, 249
- Mindful Self-Compassion program, 267, 274
- Mindfulness-based approaches, 288
- Mindfulness-Based Emotional Balance, 266
- Mindfulness-Based Stress Reduction, 267
- Minimally conscious state (MCS), 38
- Mirabegron, 67
- Miracles, 264
- Models of care, 293, 298, 300, 303
- Mood disorders, 102, 108, 111
- Moral distress, 271
- Morphine, 12, 127, 138, 234
- Motor neuron disorder (MND), 101, 102
- Multiple sclerosis (MS)
 - bowel dysfunction, 95
 - caregiver support, 96, 97
 - communication challenges, 92, 93
 - dysarthria, 94
 - dysphagia, 94
 - education and research agenda, 97
 - end of life care, 96
 - neurology, rehabilitation and palliative care services, 91
 - pain, 241
 - potential serious conversation triggers, 93
 - presentation and disease stages, 90
 - prognosis, 91, 92
 - psychological, 95
 - seizures, 94
 - severe MS, 92
 - suicide, 95, 96
 - symptoms and management
 - fatigue, 94
 - pain, 93, 94
 - spasticity, 94
 - treatment and multidisciplinary team-based care, 90
 - tremor and ataxia, 94
 - urogenital, 95
 - vertigo and dizziness, 95
- Myoclonus, 13
 - EOL, 233
 - pain, 249
- N**
- Natalizumab, 177, 181
- Near infrared spectroscopy (NIRS), 136
- Needs Assessment Tool-PD, 62
- Neurologic illness, 3
- Neurological care, 5, 6
- Neuromuscular diseases
 - advance care planning and goals of care, 105
 - ALS, 102
 - caregiver burden, 111
 - disease modifying therapy
 - edaravone, 103
 - riluzole, 103
 - DMD, 104
 - education agenda, 112
 - EOL care and hospice, 111, 112
 - estimating prognosis, 102
 - hastened death, requests for, 111
 - research agenda, 112
 - serious illness triggers, 111
 - SMA, 104
 - symptoms and management
 - cognitive dysfunction, 109
 - cramps, 109
 - dysarthria and communication issues, 109, 110
 - dysphagia, 105, 107
 - insomnia, 110
 - mood disorders, 108
 - pain, 109
 - pseudobulbar affect, 108
 - sialorrhea, 110
 - spasticity, 107
 - weakness, 108
 - withdrawing and withholding life sustaining treatments, 110, 111
- Neuro-oncology, 128
- Neuropalliative care, 2, 3
 - align incentives, 303
 - clinical efforts, 303
 - criteria for hospice, 303
 - educational efforts, 303
 - models of care, 303
 - quality measures, 303
 - research needs, 304
- Neuropathic pain, 240, 244–246, 250
- Neuroprognostication, 167
- No Evident Disease Activity (NEDA), 90
- Nociception coma, 46
- Nociceptive pain, 239
- Non-invasive positive pressure ventilation (NIV), 105, 107
- Nonsteroidal anti-inflammatory drugs, 109
- Nutrition, 15, 33, 94, 127, 127, 299
- O**
- Opioid(s), 12, 125, 246, 248
- Opioid abuse potential, assessment of, 247
- Opioid rotation, 247, 248
- Opioid-induced constipation (OIC), 248
- 5-item Opioid Risk Tool (ORT), 247
- Orthostatic hypotension, 62, 66, 67, 67
- Oscillopsia, 95
- Outpatient neurology palliative care
 - models of, 295
 - practical implementation strategies for
 - B-NAT, 298
 - clinical team checklists, 296

- Outpatient neurology palliative care (*cont.*)
- cultural barriers, 297, 298
 - funding, 297
 - gathering information, 298
 - interdisciplinary palliative team, building, 295, 297
 - models of care, 300–301
 - neurology clinics, integrating palliative care into, 294
 - outpatient neuropalliative care delivery, models of, 295
 - palliative care champion, 294
 - palliative care clinic, developing, 294
 - person-centered conversation, avoiding patient fatigue and maximizing time for, 299
 - primary palliative care skills, self-training in, 293
 - quality improvement, education and research, 300, 301
 - resource lists, 300
 - telemedicine, 300
 - after visit communication, 299, 300
- Oxcarbazepine, 245
- P**
- Pain, 32
- assessment algorithm, 242
 - assessment and communication, 241–243
 - causes, 239
 - child neurology, 138
 - corticosteroids, 249
 - EOL, 234
 - major neurological disease categories, 240, 241
 - management
 - breakthrough, 246, 247
 - neuropathic pain, 244–246
 - non-pharmacologic, 243
 - opioid, 246
 - opioid abuse potential, assessment of, 247
 - opioid rotation, 247, 248
 - targeted pharmacologic, 243, 244
 - tolerance, addiction and pseudoaddiction, 247
 - managing cancer, 244
 - mechanisms, 239
 - multiple sclerosis, 93, 94
 - neuromuscular diseases, 109
 - opioid-induced side effects, 248
 - constipation, 248
 - encephalopathy, 249
 - myoclonus, 249
 - sedation, 249
 - urinary retention, 249
 - Parkinson disease, 68
 - public health challenges, 250, 251
 - relief, procedural methods, 250
- Pain assessment in advanced dementia (PAINAD), 82, 240
- Pain control, malignant brain tumors, 127, 128
- Pain management, 32, 44–45, 143, 234, 243–244, 251
- Palliative care, 1, 91, 280, 287
- clinician-family communication, 5
 - components, 2
 - education, 69
 - integrated into neurological care, 5, 6
 - in neurological disease, 3
 - caregiver needs, 4
 - existential and psychological suffering, 4
 - illness trajectories, 3
 - prognostic uncertainty, 4
 - symptom profiles, 4
 - practice variations, 5
- Palliative Performance Scale, 164
- Palliative sedation, 193, 194
- Parkinson disease (PD), 59, 62, 65, 66, 240
- caregiver burden, 68, 69
 - defining, 61, 62
 - dysautonomia, 66, 67
 - dysphagia and sialorrhea, 67, 68
 - Edmonton symptom assessment system, 63
 - education and research agenda, 69
 - hasten death, 198
 - levodopa, withdrawal of, 68
 - managing symptoms
 - advanced illness, medication for motor symptoms, 62, 65
 - dementia, 65
 - psychosis, 65, 66
 - mortality and estimating prognosis, 60
 - pain, 68
 - palliative conversations, potential triggers for, 61
 - palliative referral, symptom burden, needs assessment and triggers for, 62
 - pharmacologic treatments, 61
 - sleep disorders, daytime sleepiness and fatigue, 66
- Parkinson's disease dementia (PDD), 74
- Paroxysmal sympathetic hyperactivity (PSH) syndrome, 13, 32
- Paternalism, 16, 18, 180, 180
- Pediatric neurologic disease, 140, 142
- Percutaneous endoscopic gastrostomy (PEG) tube, 105
- Peripherally acting μ -opioid receptor antagonists (PAMORAs), 248
- Personhood, loss of, 258, 263
- Physical well-being, 182, 282
- Physician assisted death (PAD), 188–191, 194, 195
- Practical implementation strategies, for outpatient neurology palliative care
- B-NAT, 298
 - clinical team checklists, 296
 - cultural barriers, 297, 298
 - funding, 297
 - gathering information, 298
 - interdisciplinary palliative team, building, 295, 297
 - models of care, 301
 - neurology clinics, integrating palliative care into, 294
 - outpatient neuropalliative care delivery, models of, 295
 - palliative care champion, 294
 - palliative care clinic, developing, 294

- person-centered conversation, avoiding patient fatigue and maximizing time for, 299
- primary palliative care skills, self-training in, 293
- quality improvement, education and research, 300, 301
- resource lists, 300
- telemedicine, 300
 - after visit communication, 299, 300
- Pregabalin, 123, 124, 244–246
- Primary palliative care skills, 293–294
- Prognostic discordance, 167
- Prognostic uncertainty, 137, 138, 165
- Prognostication, 91
 - communicating prognosis, 165
 - cultivating prognostic awareness, 165
 - expressing risk, methods of, 165, 166
 - prognostic discordance, 167
 - uncertainty, 166, 167
 - determination, 162, 163
 - disease-specific observational data and severity scores, 163, 164
 - neurologists' subjective assessment, 164, 165
 - education and research agenda, 167
 - importance, 161, 162
 - limitations of, 137
 - risk communication, methods of, 166
- Progressive dementia syndromes, 73
- Pseudoaddiction, 247
- Pseudobulbar affect, 102, 108
- Psychosis, 61, 62, 65–66, 69, 199
- Pulmonary embolism, 198

- R**
- Radiation therapy, 118, 125
- Regret bias, 179
- Relapsing-remitting MS (RRMS), 90
- REM sleep behavior disorder (RBD), 66
- RENEW model, 275
- Resilience
 - discovering personal resources, 265
 - qualities of
 - choice, 266
 - connection, 266
 - purpose/intention beyond self, 266
 - selected mindfulness-based and compassion-based interventions, 266, 267
 - self-care, 272
 - choice, 273
 - connection, 273
 - happiness, 273
 - personal resources, 273
 - practices, 274, 275
- Riluzole, 103
- Risk tolerance, 179

- S**
- Sadness, 126, 182
- Secondary progressive MS (SPMS), 90
- Sedation
 - malignant brain tumors, 127, 128
 - pain, 249
- Seizures, 123, 124
 - child neurology, 138
 - EOL, 231, 232
 - multiple sclerosis, 94
- Selective serotonin reuptake inhibitor (SSRI), 108
- Self-care, burnout, 272
 - adaptation, 275
 - build lifelong habits and practices of, 275, 276
 - building resilience, 272–275
 - coping strategies, 273
 - definitions, 269, 270
 - directed attention practices, 274
 - education and research agenda, 276
 - G.R.A.C.E. training, 271
 - individual skills and workplace factors, 272
 - lifestyle management techniques, 273
 - neurology and palliative care, 270
 - popular myth, de-bunking, 271
 - preventing and reducing, 271, 272
 - RAIN, 275
 - risk factors, 270, 271
 - symptoms, 270
- Self-efficacy, 273, 288
- Self-fulfilling prophecy, 163
- Self-training, 293
- Serious illness
 - communication tasks
 - delivering serious news and emotions, 152–155
 - discussing prognosis and information needs, 156
 - exploring goals of care, 157, 158
 - mapping patient's values, goals of care, 157
 - conversation triggers, 6
 - triggers, 111
- Serotonin-norepinephrine reuptake inhibitors (SNRIs), 244
- Severe acute brain injury (SABI), 11–13, 19, 264, 281
 - care, establishing goals of, 17, 18
 - caregiver support, 13, 14
 - EOL care, 19, 20
 - estimating and communicating prognosis, 14, 15
 - research agenda, 20
 - serious illness conversation triggers, 15–17
 - shared decision-making, 18
 - symptom management
 - acute setting, 12, 13
 - recommendations, 12
 - sub-acute and chronic setting, 19
 - trajectory, 14
- Sexual dysfunction, 95
- Shame, 262
- Shared decision making, 151, 157
 - child neurology, 141, 142
 - medical decision, 180, 181
- Shared decision-making, 18, 161
- Shock, 258
- Sialorrhea
 - neuromuscular diseases, 110
 - Parkinson disease, 68

- Sleep disorders, 66
 Social identity, loss of, 258
 Somatic pain, 240
 Spasticity
 multiple sclerosis, 94
 neuromuscular diseases, 107
 Spinal muscular atrophy (SMA), 104
 Spiritual well-being, 182, 261, 262
 AMEN acronym, 264
 anger and fear, 262
 cultural sensitivity, 264, 265
 diagnosis, handling, 260
 difficult emotions, 260–262
 discovering personal resources, 266
 education and research agenda, 267
 family caregivers, special issues for, 265
 guilt and shame, 262
 hope and miracles, 264
 meeting difficult emotions, 262, 263
 patients and families, building resilience for, 265
 RAIN acronym, 262
 social roles, identity and personhood, changes and threats to, 263
 somatic grounding exercises, 260
 spiritual/existential struggle, 259
 suggested words, 258–259
 triggers, 259
 uncertainty, 263, 264
 Spirituality, 257
 Status epilepticus, 13, 198
 Stereotactic radiosurgery (SRS), 118, 119
 Steroids, 124, 125
 Storming, 32
 Stroke, 2, 12, 16, 74, 171, 199, 200, 225, 241, 283
 Strong emotions, 259, 260, 263, 274–275
 Suicide, 95, 96, 196
 Surrogate decision-making, 161
- T**
 Teach back technique, 153, 176, 183
 Team-based palliative care, 297
 Telemedicine, 295, 300, 300
 Teriflunomide, 90
 Terminal agitation, 233, 235
 Terminal secretions, 235
 The Education in Palliative and End-of-life Care (EPEC) program, 293
 Tolerance, 234, 247, 263
 Tramadol, 245
 Transcutaneous electrical nerve stimulation (TENS), 243
 Traumatic brain injury (TBI), 4, 16, 26, 47, 280
 Tremor, 65, 94, 262
- U**
 Uncertainty, 178, 258, 263, 264
 Unexplained irritability, 138
- Unresponsive wakefulness syndrome (UWS),
 27, 40, 212
 Unresponsiveness, 31–32
 Upper motor neuron (UMN), 102
 Urinary incontinence, 95
 Urinary retention, 67, 128, 249
 Urinary symptoms, 62, 67
- V**
 Valproic acid, 124, 125
 Vascular dementia, 74, 76
 Vegetative state (VS), 38, 39
 Verbalization, 39
 Vertigo, 95
 Visceral pain, 240, 249, 250
 Vocalization, 30, 39
 Voluntarily stopping eating and drinking (VSED), 191,
 194, 194, 194, 200
 Voluntary active euthanasia (VAE), 188, 193, 195,
 196, 200
- W**
 Weakness
 malignant brain tumors, 124
 neuromuscular diseases, 108
 Weight loss, 20, 32, 69, 81, 81, 96
 Well-being, 123, 182, 259, 265
 Withdrawing and withholding life-sustaining treatment
 and assisted dying, 209, 210
 clinical ethics consultation, 216
 decision making, ethical criteria for
 decision-making algorithm, 211, 212
 goal-directedness, 211
 medically inappropriate treatment,
 213, 214
 patient autonomy, 214–215
 range of options to act, 210, 211
 decision-making process, 212
 definition, 207, 208
 goal of care, 211
 patient autonomy, 215
 phenomenon of, 206, 207
 practical considerations, 215, 216
 reflective algorithm, 213
 terminology, 207
- X**
 Xerostomia, 110
- Z**
 Zarit Burden Interview and Caregiver Strain Index, 83
 Zolpidem, 31, 48